Veeva Systems has had a mixed share price run, with solid gains over several years alongside more recent pullbacks. That puts the focus squarely on what investors are paying for its underlying cash flows. With the stock recently closing at US$277.20, the key issue for you is whether that price lines up with what the business can reasonably generate in cash over time.
The stock's next move may depend on whether the current US$277.20 price is adequately explained by Veeva Systems' projected cash flows when compared with its intrinsic value estimate from the Discounted Cash Flow (DCF) model.
If you want a broader yardstick for Veeva Systems and its cash flow story, compare it with other potential opportunities screened as 35 high quality undervalued stocks.
The Discounted Cash Flow (DCF) approach values Veeva Systems by projecting the cash it could generate for shareholders and adjusting that back to today. On the latest numbers, the business produced around $1.64b of free cash flow over the last twelve months, so this is not an early-stage story that relies on distant hopes. The model assumes those cash flows keep growing over time rather than shrinking, which fits a subscription driven software model where renewals and add ons can support a steady pipeline.
Analyst forecasts in the DCF include higher free cash flow by 2031, with growth tapering in later years so the curve resembles that of a maturing franchise rather than a hyper growth venture. When those projected cash streams are discounted back and compared with the current US$277.20 share price, the DCF output sits modestly above where the stock trades today, which is what the detailed valuation summary is built to show. Find out what Veeva Systems could be worth using our Discounted Cash Flow (DCF) estimate.
Narratives for Veeva Systems pick up where that cash flow puzzle leaves off, by spelling out which paths for growth, profitability and earnings would need to play out for the stock to look materially higher or lower than today’s price. These narratives sit on Simply Wall St’s Community page. Each narrative links its number to a specific view on how Veeva Systems' expansion, margins and risk profile could evolve, giving you a reference point you can revisit as fresh information arrives.
Veeva Systems splits opinion, with one view seeing unusually durable cash flows and another arguing the current price leaves little room for execution slip ups.
Bull case: 28% undervalued
According to John_Eric, a Simply Wall St Community investor, the core appeal of Veeva Systems starts with where its software sits in drug development.
"Drug companies operate in an environment where data integrity, audit trails, controlled workflows, documentation, and regulatory compliance are essential. Moving systems is not simply an IT project..."
Discover why this Narrative puts Veeva Systems at 28% undervalued.
Bear case: 13% overvalued
The bearish analyst Narrative on Simply Wall St frames Veeva Systems as a high quality business already priced for very strong execution.
"The numbers indicate that Veeva Systems' share price already reflects revenue growth that is higher than the mid teens pace described for fiscal 2027..."
Explore why this Narrative puts Veeva Systems at 13% overvalued.
Valuation work only tells part of the Veeva Systems story, and the research here also flags specific concerns that a careful shareholder would want to weigh for themselves. Take a closer look at 1 warning sign before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com